Trials / Completed
CompletedNCT01321671
Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers
The Pharmacokinetics Of Pregabalin Controlled Release Formulation In Fed State Compared To The Controlled Release And Immediate Release Formulations In The Fasted State
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics of a single dose of a pregabalin controlled release (CR) tablet administered fasted in the evening relative to a single dose of the CR tablet administered immediately following a 600 to 750 calorie evening meal. The single dose pharmacokinetics of the pregabalin CR administered fed or fasted will also be compared to the single dose pharmacokinetics of the pregabalin immediate release (IR) capsule. In addition, the safety and tolerability of these 3 treatments will be evaluated.
Detailed description
Evaluate the absorption, pharmacokinetics, safety/tolerability of a single dose of a pregabalin CR tablet under various conditions as compared to single dose of pregabalin IR capsule
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin controlled release, 330 mg, 600- 750 calorie | A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal |
| DRUG | Pregabalin controlled release, 330 mg, fasted | A single oral dose of 330 mg controlled release tablet administered fasted in the evening |
| DRUG | Pregabalin immediate release, 300 mg | A single oral dose of 300 mg immediate release capsule administered in the evening |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2011-03-23
- Last updated
- 2021-01-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01321671. Inclusion in this directory is not an endorsement.